TY - JOUR
T1 - Cost-effectiveness of newborn screening for cystic fibrosis determined with real-life data
AU - van der Ploeg, C. P B
AU - van den Akker-van Marle, M. E.
AU - Vernooij-van Langen, A. M M
AU - Elvers, L. H.
AU - Gille, J. J P
AU - Verkerk, P. H.
AU - Dankert-Roelse, J. E.
AU - Dankert-Roelse, J. E.
AU - Vernooij-van Langen, A. M M
AU - Loeber, J. G.
AU - Elvers, L. H.
AU - Triepels, R. H.
AU - Gille, J. J P
AU - Van der Ploeg, C. P B
AU - van der Pal, S. M.
AU - Dompeling, E.
AU - Pals, G.
AU - van den Akker van Marle, M. E.
AU - Gulmans, V. A M
AU - Oey-Spauwen, M. J W
AU - Wijnands, Y. H H M
AU - Castricum, L. M.
AU - Arets, H. G M
AU - van der Ent, C. K.
AU - Tiddens, H. A W M
AU - de Rijke, Y. B.
AU - Yntema, J. B.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - Background: Previous cost-effectiveness studies using data from the literature showed that newborn screening for cystic fibrosis (NBSCF) is a good economic option with positive health effects and longer survival. Methods: We used primary data to compare cost-effectiveness of four screening strategies for NBSCF, i.e. immunoreactive trypsinogen-testing followed by pancreatitis-associated protein-testing (IRT-PAP), IRT-DNA, IRT-DNA-sequencing, and IRT-PAP-DNA-sequencing, each compared to no-screening. A previously developed decision analysis model for NBSCF was fed with model parameters mainly based on a study evaluating two novel screening strategies among 145,499 newborns in The Netherlands. Results: The four screening strategies had cost-effectiveness ratios varying from €23,600 to €29,200 per life-year gained. IRT-PAP had the most favourable cost-effectiveness ratio. Additional life-years can be gained by IRT-DNA but against higher costs. When treatment costs reduce with 5% due to early diagnosis, screening will lead to financial savings. Conclusion: NBSCF is as an economically justifiable public health initiative. Of the four strategies tested IRT-PAP is the most economic and this finding should be included in any decision making model, when considering implementation of newborn screening for CF.
AB - Background: Previous cost-effectiveness studies using data from the literature showed that newborn screening for cystic fibrosis (NBSCF) is a good economic option with positive health effects and longer survival. Methods: We used primary data to compare cost-effectiveness of four screening strategies for NBSCF, i.e. immunoreactive trypsinogen-testing followed by pancreatitis-associated protein-testing (IRT-PAP), IRT-DNA, IRT-DNA-sequencing, and IRT-PAP-DNA-sequencing, each compared to no-screening. A previously developed decision analysis model for NBSCF was fed with model parameters mainly based on a study evaluating two novel screening strategies among 145,499 newborns in The Netherlands. Results: The four screening strategies had cost-effectiveness ratios varying from €23,600 to €29,200 per life-year gained. IRT-PAP had the most favourable cost-effectiveness ratio. Additional life-years can be gained by IRT-DNA but against higher costs. When treatment costs reduce with 5% due to early diagnosis, screening will lead to financial savings. Conclusion: NBSCF is as an economically justifiable public health initiative. Of the four strategies tested IRT-PAP is the most economic and this finding should be included in any decision making model, when considering implementation of newborn screening for CF.
KW - Cost-effectiveness
KW - Cystic fibrosis
KW - Newborn screening
UR - https://www.scopus.com/pages/publications/84924286082
U2 - 10.1016/j.jcf.2014.08.007
DO - 10.1016/j.jcf.2014.08.007
M3 - Article
C2 - 25213034
AN - SCOPUS:84924286082
SN - 1569-1993
VL - 14
SP - 194
EP - 202
JO - Journal of Cystic Fibrosis
JF - Journal of Cystic Fibrosis
IS - 2
ER -